Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives

2012 ◽  
Vol 39 (4) ◽  
pp. 493-502 ◽  
Author(s):  
Andrew X. Zhu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Current Status ◽  
Advanced Hepatocellular Carcinoma ◽  
Future Perspectives ◽  
Molecularly Targeted Therapy

scholarly journals New agents on the horizon in hepatocellular carcinoma

2012 ◽  
Vol 5 (1) ◽  
pp. 41-50 ◽  
Author(s):  
Andrew X. Zhu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Iii ◽  
Current Status ◽  
Advanced Hepatocellular Carcinoma ◽  
Targeted Agents ◽  
New Agents ◽  
The Past ◽  
Early Evidence ◽  
Molecularly Targeted Agents ◽  
Active Research

Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.

Sign in / Sign up

Export Citation Format

Share Document